Bloodstream infections (BSI) are curable with off-the-shelf antibiotics - but only if the pathogen causing the infection is accurately identified early on. If not, BSI can quickly develop into sepsis, which only approx. 50% of patients survive - and which one of the most expensive conditions to treat because patients require intensive care unit (ICU) support for 7-14 days, and average hospital length of stay for survivors is 3-5 weeks. A rapid and accurate test for BSI is not available today and is considered the holy grail of diagnostics. The market for such a test is estimate to be worth 1 billion USD a year. Stender Diagnostics has taken important and validated steps towards the development and regulatory approval of such a test. AntibioDx is a unique in vitro diagnostic test for rapid and accurate identification of pathogens in the bloodstream. The AntibioDx device delivers the information doctors need, when they need it - which is within 1 hour of suspecting a bloodstream infection (BSI). AntibioDx will remove guesswork from the clinical decision-making process and will ensure doctors make the right decision, both in terms of whether to treat and how to treat. Both money and lives will be saved.
Looking for a particular Stender Diagnostics employee's phone or email?
The Stender Diagnostics annual revenue was $400000 in 2026.
Stender Diagnostics is based in Gentofte, Capital Region.
The NAICS codes for Stender Diagnostics are [3254, 325, 32, 325413, 32541].
The SIC codes for Stender Diagnostics are [283, 28].